Alembic Pharmaceuticals Limited
has received approval from the US Food & Drug Administration (USFDA) for its following Abbreviated New Drug Applications (ANDAs):
The pharma company has received final approval from USFDA to market Deferasirox tablets, 90 mg and 360 mg. This medication is used to treat a chronic iron overloaded due to blood transfusions in patients 2 years of age and older.
Further, the pharma company said final approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg, 500 mg and tentative approval for Deferasirox Tablets 180 mg.
Alembic now has a total of 107 ANDA approvals (95 final approvals and 12 tentative approvals) from USFDA.
Alembic Pharmaceuticals Ltd is currently trading at Rs550 up by Rs3.5 or 0.64% from its previous closing of Rs546.50 on the BSE.
The scrip opened at Rs551 and has touched a high and low of Rs559.10 and Rs545.50 respectively.